Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis

被引:0
作者
Aleš Bartoš
Lenka Fialová
Jiřina Soukupová
Jaromír Kukal
Ivan Malbohan
Jiří Piťha
机构
[1] University Hospital Královské Vinohrady,Charles University in Prague, Third Faculty of Medicine, Dept. of Neurology
[2] Charles University,1st Faculty of Medicine, Institute of Medical Biochemistry
[3] Charles University,1st Faculty of Medicine, Institute of Clinical Biochemistry and Laboratory Diagnostics
[4] Institute of Chemical Technology,Dept. of Computing and Control Engineering
来源
Journal of Neurology | 2007年 / 254卷
关键词
multiple sclerosis; neurofilament; antibody; intrathecal synthesis; cerebrospinal fluid;
D O I
暂无
中图分类号
学科分类号
摘要
Neurofilaments are cytoskeletal proteins localized within axons, which may interact with the immune system during and following tissue destruction in multiple sclerosis (MS). Antibodies against the medium neurofilament subunit synthesized intrathecally may reflect axonal damage in MS patients. Both immunoglobulin G (IgG) and M (IgM) responses against the purified native medium subunit of neurofilaments (NFM) using enzyme-linked immunosorbent assay (ELISA) were determined in paired serum and cerebrospinal fluid samples obtained from 49 MS patients, 16 normal controls (CN), 21 control patients with miscellaneous diseases (CD) and 14 patients with neurodegenerative disorders (CDEG). Intrathecal production of IgM and IgG antibodies to NFM were elevated in MS patients compared with the CN or CD groups (p < 0.04 for IgM, p < 0.01 for IgG). The increase was present in all the MS courses (relapsing-remitting, primary and secondary progressive). Similar local anti-NFM IgG and IgM synthesis occurred in the MS and CDEG groups. MS patients with short and long disease duration did not differ in terms of their anti-NFM IgM and IgG responses. Repeated examinations showed stable intrathecal anti-NFM production. Intrathecal IgG and IgM antibodies against NFM were increased in MS patients and may serve as a potential marker for axonal pathology. The extent of anti-NFM levels did not correspond to any individualized clinical profiles of MS patients.
引用
收藏
页码:20 / 25
页数:5
相关论文
共 184 条
[21]  
Narayanan S(2005)Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study J Neurol Neurosurg Psychiatry 76 206-11
[22]  
Francis GS(1983)New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 227-31
[23]  
Arnaoutelis R(2005)Pathogenesis of multiple sclerosis Curr Opin Neurol 18 225-30
[24]  
Tartaglia MC(2001)Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs J Neurol Sci 184 101-22
[25]  
Antel JP(2005)Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity Neurology 64 1144-51
[26]  
Matthews PM(2002)Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability J Neuroimmunol 122 132-9
[27]  
Arnold DL(2002)Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit Neurology 58 1372-81
[28]  
Evangelou N(1998)Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis Neurobiol Aging 19 205-16
[29]  
Esiri MM(1998)Axonal transection in the lesions of multiple sclerosis N Engl J Med 338 278-85
[30]  
Smith S(1998)Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis Neurology 50 1282-8